Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results

Valerie Yu, Dhruva Bhattacharya, Andrew Webster, Aditi Bauskar, Charles Flowers, Martin Heur, Shravan K. Chintala, Tatsuo Itakura, Mark R. Wilson, Joseph T. Barr, Shinwu Jeong, Mingwu Wang, M. Elizabeth Fini

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the relationship between tear concentration of the homeostatic protein clusterin (CLU) and dry eye signs and symptoms, and to characterize tear CLU protein. Methods: Two independent studies were conducted, one in Tucson (44 subjects), the other in Los Angeles (52 subjects). A cohort study design was employed to enroll patients without regard to dry eye diagnosis. Dry eye signs and symptoms were assessed using clinical tests. Tear samples were collected by Schirmer strip, and also by micropipette at slit lamp when possible. CLU from both sample types was quantified by immunoassay. The relationship between CLU concentration and clinical test scores was determined by Pearson's correlation coefficient (for individual eyes) and multiple linear regression analysis (including both eyes). CLU was also evaluated biochemically by western blotting. Results: In the Tucson cohort, a positive correlation was observed between tear CLU concentration and results of the Schirmer strip test, a measure of tear flow (p = 0.021 includes both eyes). This result was corroborated in the Los Angeles cohort (p = 0.013). The mean tear CLU concentration was 31 ± 14 μg/mL (n = 18 subjects, 33 eyes; range = 7–48 μg/mL). CLU from clinical tear samples appeared biochemically similar to CLU from a non-clinical tear sample and from blood plasma. Conclusions: Results support the hypothesis that an optimal concentration of tear CLU is important for ocular surface health, and that this drops below the effective threshold in dry eye. Tear CLU measurement might identify patients that could benefit from supplementation. Information about concentration will aid development of therapeutic dosage parameters.

Original languageEnglish (US)
Pages (from-to)478-486
Number of pages9
JournalOcular Surface
Volume16
Issue number4
DOIs
Publication statusPublished - Oct 1 2018

    Fingerprint

Keywords

  • Clusterin
  • Dry eye
  • MMP inhibitor
  • Molecular chaperone
  • Ocular surface disease
  • Schirmer test
  • Tears

ASJC Scopus subject areas

  • Ophthalmology

Cite this